Solomon Moshkevich

President of ClinicalDiagnostics sells 3,000 NTRA shares for $818.7K under 10b5-1 plan; holds 134.6K shares post-sale

Solomon Moshkevich sold 3,000 shares across three separate transactions on 2026-07-01 at prices ranging from $267.18 to $274.06, realizing $818,710.50, leaving him with 134,643 shares. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, meaning the transaction was scheduled rather than discretionary. His prior sales at Natera show consistent post-sale gains (30-day returns of +25.2%, +26.0%, +26.2%, +27.0%, and +11.2%), though these are outcome observations rather than timing indicators for this scheduled sale. The company is currently unprofitable with net income of $-85,091,000 in the latest quarter, but annual revenue growth stands at +35.9%, and the stock has risen +31.8% over the past 30 days and +35.6% over 90 days.

NTRA president sells 3,000 shares for $655,294.81 under 10b5-1 plan; stock now -17.4% from 52-week high

Solomon Moshkevich, president of ClinicalDiagnostics at Natera, executed 4 separate sales totaling 3,000 shares for $655,294.81 at prices ranging from $217.52 to $220.67 on 2026-06-01, reducing his holdings by 2.1% to 137,643 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, making it scheduled rather than discretionary. The current stock price of $211.85 reflects a -17.4% decline from the 52-week high of $256.36, and while the company reported strong annual revenue growth of +35.9%, it remains unprofitable with a net income of $-85.1M in the latest full fiscal year. Investors should note the non-discretionary nature of this sale and the company's unprofitable status despite robust top-line growth.

NTRA President Moshkevich Solomon sold 3,000 shares for $610,065.16 via scheduled 10b5-1 plan

Moshkevich Solomon, President of Clinical Diagnostics at Natera Inc., executed 6 separate sales totaling 3,000 shares for $610,065.16 on 2026-05-01 at blended average price $203.36, reducing his holdings by 2.1% to 142,295 shares. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, meaning it is scheduled rather than discretionary. His prior trades at NTRA (5 sells) show subsequent 30-day and 90-day returns of +2.0% and +0.5% on average, while his broader cross-ticker track record across 20 prior sells shows average 90-day returns of -7.7%, suggesting mixed historical outcomes. With NTRA trading at $204.21 (down 19.7% from its 52-week high of $254.40 but up 5.8% over 30 days), and the company reporting negative net income of $-255,418,000.00 despite strong annual revenue growth of +272.3%, this scheduled disposition provides limited signal independent of the pre-arranged timing.

NTRA President Solomon Moshkevich sold 3,000 shares across 3 transactions for $606,899.48; holds 147.9K shares post-sale

Moshkevich executed three separate sales on 2026-04-01 at prices ranging from $201.32 to $203.31, generating $606,899.48 at a blended average of $202.30. This represents a 2.0% reduction of his holdings (from 150.9K to 147.9K shares). His same-ticker history at NTRA shows 5 prior sales, with recent trades on 2026-03-02 showing modest 30-day positive returns (+1.1% to +2.2%), while earlier February sales posted negative 30-day returns (-12.0% to -14.6%). His cross-ticker track record demonstrates strong timing discipline with a 100.00% well-timed rate across 20 prior sells (avg 90d return -12.2%), though notably none of his NTRA-specific prior sales have yet reached measurable 90-day outcomes. Natera remains unprofitable (net income $-87.5M on revenue $592.2M) despite strong annual revenue growth of +35.9%, providing context for insider activity at a high-growth biotech generating significant losses.

President of Clinical Diagnostics sells 3,000 NTRA shares for $599,545.06; stock down 10.4% in 30 days, company unprofitable.

Moshkevich Solomon, President of Clinical Diagnostics, executed 3 separate sales totaling 3,000 shares for $599,545.06 on 2026-03-02 at a blended average price of $199.85. The stock has since declined 10.4% over 30 days and 13.1% over 90 days from the current price of $207.04, trading at 18.6% below its 52-week high of $254.40. His holding of 150,023 shares post-transaction represents a 2.0% reduction from prior holdings. Notably, NTRA remains unprofitable with negative net income of $-87,544,000.00 in the latest quarter, despite strong annual revenue growth of 35.9%, providing context for insider liquidity decisions in a high-growth but currently loss-making enterprise.

NTRA President Moshkevich sells 3,000 shares for $694.3K under pre-arranged 10b5-1 plan

Moshkevich Solomon, President of Clinical Diagnostics at Natera, Inc., executed 6 separate sales totaling 3,000 shares for $694,309.17 on 2026-02-02, reducing his holdings from 142.5K shares to 139.5K shares. This transaction was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, indicating the sales were scheduled and not discretionary. The multi-tranche execution at prices ranging from $228.50 to $234.00 (blended average $231.44) across a single trading day represents a routine programmatic disposition under plan mechanics, not an open-market signal driven by current valuation assessment or insider conviction. The 2.1% reduction in holdings remains modest relative to his remaining 139.5K share position.

NTRA: Moshkevich sells 2,951 shares for $675,621.47; holds 123.5K shares post-sale

Moshkevich Solomon (President, Clinical Diagnostics at Natera) executed 2 separate sales totaling 2,951 shares for $675,621.47 at an average of $228.95, representing a 2.3% reduction in holdings to 123.5K shares. The sale occurred as the stock trades at $248.74, approximately at its 52-week high, having gained 44.5% over the prior 90 days. His same-ticker trade history at NTRA shows 5 prior sells, all clustered around early December 2025, with near-term 30-day returns ranging from -3.4% to -4.4%; however, 90-day outcomes remain unmeasurable for most. His cross-ticker track record shows a 66.67% well-timed sell rate across 20 prior open-market dispositions, though average 90-day returns were marginally positive at +0.5%. Natera remains unprofitable on a full-year basis ($-87.5M net income) despite strong 56.8% annual revenue growth, warranting attention to whether insider activity reflects confidence in near-term execution or selective profit-taking at elevated valuations.

President Moshkevich sold 3,000 NTRA shares in 4 transactions for $714,458.78; stock up 20.2% in 30 days, 43.0% in 90 days

Moshkevich Solomon, President of Clinical Diagnostics at Natera, executed 4 separate sales totaling 3,000 shares for $714,458.78 at blended average price $238.15, reducing his holdings by 2.7% to 109,061 shares. The sales occurred as NTRA stock is up +20.2% over 30 days and +43.0% over 90 days from transaction date, trading near its 52-week high of $238.81. His prior 5 trades at NTRA show mixed results: 2 of 2 measurable 90-day outcomes were well-timed (stock fell after his sales on 2025-07-01), while his most recent 3 sales on 2025-11-03 (completed just 28 days before this filing) show 30-day gains of +19.3% to +20.3%, suggesting those sales were executed into significant strength. The timing pattern warrants observation but does not definitively signal conviction about valuation; the company remains unprofitable with net income of $-87,544,000.00 despite 56.8% annual revenue growth.

President of ClinicalDiagnostics sells 3,000 NTRA shares for $595,810.04 at blended $198.60; 4 of 5 prior NTRA sales were well-timed.

Moshkevich Solomon, President of ClinicalDiagnostics at Natera, filed 3 separate sales totaling 3,000 shares (3.0K shares) for $595,810.04 on 2025-11-03 at a blended average price of $198.60, reducing holdings by 2.6% to 112,061 shares. The stock currently trades at $196.45, down slightly from the transaction prices, and is within 1.2% of its 52-week high of $198.93. Notably, this insider has a strong track record at NTRA specifically: 4 of 5 prior sales at this ticker demonstrated negative 90-day returns, indicating the timing pattern was well-timed (the stock fell after those sales). His cross-ticker track record shows an average 90-day return of +1.4% following 16 prior sells across all holdings. The company remains unprofitable (net income $-100.9M in the latest full fiscal year) despite strong revenue growth of +56.8% and 546.6M in latest-quarter revenue. His sale pattern at NTRA—selling near recent highs, with prior sales preceding downturns—warrants investor monitoring for any emerging operational or market headwinds specific to the diagnostic business.

President of Clinical Diagnostics sells 3,000 NTRA shares for $500.3K at blended avg $166.77; post-transaction holds 130.2K shares.

Moshkevich Solomon executed 4 separate sales totaling 3,000 shares for $500,304.91 on 2025-07-01, reducing his holdings by 2.3% from 133.2K to 130.2K shares. The blended average price of $166.77 sits above the current price of $161.76, but near the 52-week high of $177.00, which the stock is 8.6% below. His prior 5 sales at NTRA occurred on 2025-03-05 and 2025-01-29; reviewing their 90-day outcomes, only 1 of 5 prior transactions at this ticker proved well-timed (stock declined after the sale), suggesting mixed execution timing historically at this security. The company remains unprofitable on a full-year basis despite strong 56.8% annual revenue growth and a $22.1B market cap, creating a backdrop of continued operational losses that may inform liquidity management decisions.